Akers Biosciences and MyMD Pharmaceuticals Announce Definitive Merger Agreement
November 12, 2020
Akers Biosciences (NASDAQ: AKER) and MyMD Pharmaceuticals have entered into a definitive merger agreement that will combine the two companies into a single Nasdaq-listed company to be renamed MyMD Pharmaceuticals, Inc. The transaction, expected to close in H1 2021, gives current MyMD shareholders approximately 80% of the combined company and is intended to provide MyMD access to public capital and Akers' resources to accelerate development and commercialization of MyMD's immunotherapy pipeline.
- Buyers
- Akers Biosciences, Inc.
- Targets
- MyMD Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- Maryland, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Merck Acquires Acceleron Pharma for $11.5 Billion
September 30, 2021
Biotechnology
Merck has entered into a definitive agreement to acquire Acceleron Pharma Inc. for $180 per share in cash, representing an approximate total equity value of $11.5 billion. The acquisition brings Acceleron's late-stage sotatercept program (for pulmonary arterial hypertension) and its REBLOZYL portfolio into Merck's cardiovascular pipeline, subject to tender offer completion and customary regulatory approvals.
-
Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)
October 26, 2020
Biotechnology
Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.
-
ICON plc Acquires MolecularMD Corporation
February 21, 2019
Healthcare Services
ICON plc acquired MolecularMD Corporation, a molecular diagnostic specialty laboratory, to expand ICON's molecular diagnostic testing capabilities—including next-generation sequencing and immunohistochemistry—and strengthen support for oncology drug–diagnostic co-development. The acquisition integrates MolecularMD's central laboratory services and client base into ICON's global laboratory network to support precision medicine programs across clinical development phases.
-
Quanterix Corporation Acquires Akoya Biosciences
July 8, 2025
Medical Devices
Quanterix Corporation has completed its acquisition of Akoya Biosciences, combining Quanterix's ultra‑sensitive blood biomarker detection platform with Akoya's spatial biology imaging and reagents. Under the amended merger agreement, Quanterix issued approximately 7.8 million shares and paid about $20 million in cash to Akoya equity holders; the combined business is expected to expand the company's served addressable market and accelerate the path to profitability.
-
BioPharmX Corp to Merge with Timber Pharmaceuticals
January 28, 2020
Pharmaceuticals
BioPharmX Corporation (NYSE American: BPMX) entered into a definitive merger agreement with Timber Pharmaceuticals LLC whereby a BioPharmX subsidiary will merge into Timber, leaving Timber as a wholly‑owned subsidiary of BioPharmX. The transaction will bring at least $20 million of financing to the combined company, after which BioPharmX will change its name to Timber Pharmaceuticals and Timber’s management will become the combined company's leadership.
-
WebMD Health Corp Acquires Mercury Healthcare
June 29, 2022
Healthcare Services
WebMD Health Corp has acquired Mercury Healthcare, a Vestar Capital-backed healthcare marketing technology and analytics company. The deal brings Mercury's patient engagement, targeting and analytics capabilities into WebMD's content and audience platform to accelerate personalized patient engagement and marketing solutions for health systems and providers.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.